Key result
Diabetes genetic risk score does not interact with statin therapy to affect rapid CAC progression.
Why the study?
HMG-CoA-reductase inhibitors increase coronary artery calcification progression and the risk of developing diabetes mellitus, but whether their intake interacts with diabetes-associated genetic risk to affect calcification progression was unknown.
Does HMG-CoA-reductase inhibitor intake interact with a diabetes-associated genetic risk score to affect the rapid progression of coronary artery calcification?
Cohort (n=3,157)
Does HMG-CoA-reductase inhibitor intake interact with a diabetes-associated genetic risk score to affect the rapid progression of coronary artery calcification?
The impact of statins on the progression of coronary artery calcification does not appear to be modified by a patient's genetic risk for developing diabetes mellitus.
Answers are grounded in this paper and cite their sources.
No interaction seen in this cohort; leaves open whether diabetes GRS modifies statin effects on CAC progression.
HMG-CoA-Reductase inhibitors (HMGRIs) are currently the most widely used group of drugs in patients with coronary artery disease (CAD) and are given preemptively to patients with high levels of cholesterol, including those with diabetes mellitus (DM). However, intake of HMGRIs also increases the progression of coronary artery calcification (CAC) and the risk of developing DM. This study aimed to investigate whether HMGRI intake interacts with the diabetes-associated genetic risk score (GRS) to affect CAC progression using data from the population-based Heinz Nixdorf Recall (HNR) study. CAC was measured in 3157 participants using electron-beam computed tomography twice, at baseline (CAC b ) and 5 years later (CAC 5y ). CAC progression was classified as slow, expected, or rapid based on predicted values. Weighted DM GRS was constructed using 100 diabetes mellitus–associated single nucleotide polymorphisms (SNPs). We used log-linear regression to evaluate the interaction of HMGRI intake with diabetes-associated GRS and individual SNPs on CAC progression (rapid vs. expected/slow), adjusting for age, sex, and log(CAC b + 1). The prevalence of rapid CAC progression in the HNR study was 19.6%. We did not observe any association of the weighted diabetes mellitus GRS with the rapid progression of CAC (relative risk (RR) [95% confidence interval (95% CI)]: 1.01 [0.94; 1.10]). Furthermore, no indication of an interaction between GRS and HMGRI intake was observed (1.08 [0.83; 1.41]). Our analyses showed no indication that the impact of HMGRIs on CAC progression is significantly more severe in patients with a high genetic risk of developing DM than in those with a low GRS.
No takes yet. Share an insight, caveat, or question.
Pechlivanis et al. (2021) conducted a cohort in Coronary artery calcification (n=3,157). HMG-CoA-reductase inhibitors (HMGRIs) and Diabetes Mellitus Genetic Risk Score (DM GRS) vs. Non-HMGRI users / Low DM GRS was evaluated on Rapid progression of coronary artery calcification (interaction of HMGRI intake and DM GRS) (RR 1.08, 95% CI 0.83-1.41, p=0.56). The diabetes-associated genetic risk score did not interact with HMG-CoA-reductase inhibitor intake to affect the rapid progression of coronary artery calcification.
Synapse has enriched 10 related papers. Consider them for comparative context: